| Literature DB >> 18260618 |
Wei Meng1, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Ravindar N Girotra, Gang Wu, Philip M Sher, Eamonn P Morrison, Scott A Biller, Robert Zahler, Prashant P Deshpande, Annie Pullockaran, Deborah L Hagan, Nathan Morgan, Joseph R Taylor, Mary T Obermeier, William G Humphreys, Ashish Khanna, Lorell Discenza, James G Robertson, Aiying Wang, Songping Han, John R Wetterau, Evan B Janovitz, Oliver P Flint, Jean M Whaley, William N Washburn.
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18260618 DOI： 10.1021/jm701272q
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446